Keratosis Composition Targeting Hyperkeratosis and Acantholysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for keratosis, such as Darier's disease, psoriasis, and actinic keratosis, are inadequate in effectively addressing hyperkeratosis, dyskeratosis, and acantholysis, leading to severe symptoms like itching, pain, and thickening of the skin, with limited improvement in clinical scores and quality of life indices.
Innovation Solution
A pharmaceutical composition containing 5-methyl-2-(1-piperazinyl)benzenesulfonic acid, in various forms, is administered to treat or prevent keratosis by suppressing hyperkeratosis, dyskeratosis, and acantholysis, improving clinical symptoms and quality of life indices through targeted molecular interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for keratosis are used, then the skin condition is treated to some extent, but the effectiveness is insufficient and severe symptoms persist
Solution Approach 1:
The patent introduces a novel chemical compound (5-methyl-2-(1-piperazinyl)benzenesulfonic acid) with specific molecular properties that change the treatment parameter profile. This compound targets multiple pathological mechanisms simultaneously (hyperkeratosis, dyskeratosis, acantholysis) through its unique chemical structure, achieving superior treatment effectiveness and symptom relief compared to conventional treatments.
2Ease of operation
If current pharmaceutical compositions are used, then keratosis symptoms are managed, but clinical scores and quality of life indices show limited improvement
Solution Approach 1:
The patent compound exhibits multi-functional activity by simultaneously addressing multiple keratosis-related mechanisms: suppressing hyperkeratosis (excessive keratin production), dyskeratosis (abnormal keratinization), and acantholysis (cell detachment). This universal approach across multiple pathological pathways results in comprehensive symptom relief and significant improvement in both clinical scores and quality of life indices.
Data Source
AI summary
A pharmaceutical composition for keratosis contains 5-methyl-2-(1-piperazinyl)benzenesulfonic acid. The compound may be in a form of an anhydrate thereof, a salt thereof, a hydrate or solvate thereof, or a hydrate or solvate of a salt thereof, and the hydrate is, for example, 5-methyl-2-(1-piperazinyl)benzenesulfonic acid monohydrate. The keratosis is, for example, Darier's disease or psoriasis.